Zacks Investment Research Downgrades OpGen (OPGN) to Hold

OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, reports.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Alliance Global Partners assumed coverage on OpGen in a research report on Friday, March 1st. They issued a “buy” rating and a $2.30 price objective for the company.

Shares of OPGN opened at $0.53 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.32 and a quick ratio of 1.20. OpGen has a 52-week low of $0.52 and a 52-week high of $2.90. The company has a market capitalization of $4.61 million, a P/E ratio of -0.24 and a beta of 1.04.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings data on Tuesday, February 26th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.09). OpGen had a negative net margin of 453.73% and a negative return on equity of 232.38%. Equities analysts forecast that OpGen will post -0.87 EPS for the current year.

In other OpGen news, CEO Evan/ Fa Jones acquired 417,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $250,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 7.10% of the stock is currently owned by insiders.

An institutional investor recently bought a new position in OpGen stock. Virtu Financial LLC acquired a new stake in OpGen Inc (NASDAQ:OPGN) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 115,918 shares of the medical research company’s stock, valued at approximately $70,000. Virtu Financial LLC owned 1.34% of OpGen as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.81% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Further Reading: Gap Up Stocks

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.